Candela Corporation

Candela Corporation, also known as Candela Medical, is a leading global medical aesthetic device company established in 1970 in Boston, USA, with its headquarters in Marlborough, Massachusetts. The company has a complex ownership history, having gone public in 1986. In 2009, it was acquired by Syneron Medical Ltd. for approximately $65 million, becoming a wholly-owned subsidiary. Subsequently, Apax Partners acquired the combined entity in July 2017 for about $400 million. Candela filed for a $250 million IPO in October 2021 but withdrew its plans in September 2022. As of 2021, Candela employed approximately 860-900 individuals and reported revenues of $389.7 million in 2019 and $321.6 million in 2020, with an estimated $600 million for 2024.

Candela designs, manufactures, and markets medical aesthetic devices that utilize laser, Intense Pulsed Light (IPL), and Radiofrequency (RF) microneedling technologies. Their product portfolio supports a wide range of aesthetic and medical treatments including hair removal, vascular lesion treatment (such as spider veins, rosacea, and port wine stains), tattoo removal, skin rejuvenation, and the treatment of benign pigmented lesions. Key product lines include the Gentle Pro Series, PicoWay, Vbeam, Nordlys, Matrix, Profound, and CO2RE. The company sells its products globally, serving plastic surgeons, dermatologists, hospitals, and medical spas in nearly 100 countries.

In terms of patent litigation, Candela Corporation appears to be an operating company actively asserting its intellectual property rights. The provided data indicates Candela Corporation has been a plaintiff in one tracked case and a defendant in zero cases. This posture aligns with a company protecting its core technologies.

The sole tracked case involving Candela Corporation is Candela Corporation et al. v. Nikolai Tankovich, filed on November 18, 2022, before the Patent Trial and Appeal Board (PTAB), where Candela Corporation is listed as the plaintiff. This case suggests Candela is involved in challenging or asserting the validity of patent claims relevant to its medical aesthetic laser and energy-based device technologies.